Comparison of the effect of lipid A analog E5531 and the lipid a from Escherichia coli on phospholipid membrane properties

被引：0
|
作者：
Asai, Y [1 ]
Watanabe, S
机构：
[1] Eisai & Co Ltd, Formulat Res Lab, Kawashima, Gifu 5016195, Japan
[2] Eisai & Co Ltd, Tsukuba Res Labs, Tsukuba, Ibaraki 3002635, Japan
来源：
DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY | 2000年 / 26卷 / 02期
关键词：
fluidity; lipid A; phase transition temperature; phospholipid membrane; size;
D O I：
10.1081/DDC-100100345
中图分类号：
R914 [药物化学];
学科分类号：
100701 ;
摘要：
The effect of the lipid A analog E5531 on the phospholipid membrane was compared with that of the lipid A from Escherichia coli (EC). E5531 decreased the phase transition temperature of dipalmitoylphosphatidylcholine (DPPC) membrane and increased the fluidity and micropolarity. On the other hand, the effect of EC on the membrane was contradictory. These results suggested that the reason for the difference of biological effects of these two lipid A would be caused by the differences from the effect on the cell membranes.
引用
收藏
页码：199 / 204
页数：6
相关论文
共 50 条
  • [1] The effect of the lipid A analog E5531 on phospholipid membrane properties
    Asai, Y
    Iwamoto, K
    Watanabe, S
    FEBS LETTERS, 1998, 438 (1-2): : 15 - 20
  • [2] The effect of lipid A analog E5531 on membrane properties of dipalmitoylphosphatidylcholine
    Asai, Y
    Watanabe, S
    DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY, 2000, 26 (08) : 907 - 912
  • [3] The effect of the lipid A analog, E5531 on fever induced by endotoxin from Escherichia coli
    Asai, Y
    Nozu, Y
    Ikeuchi, T
    Narazaki, R
    Iwamoto, K
    Watanabe, S
    BIOLOGICAL & PHARMACEUTICAL BULLETIN, 1999, 22 (04) : 432 - 434
  • [4] Effect of divalent cations on the membrane properties of the lipid A analog E5531
    Asai, Y
    Watanabe, S
    DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY, 1999, 25 (10) : 1107 - 1113
  • [5] The effect of the membrane fluidity on pharmacokinetics for lipid A analog E5531
    Asai, Y
    Sano, Y
    Kikuchi, K
    Watanabe, S
    DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY, 2000, 26 (04) : 383 - 390
  • [6] Preparation of transparent injectable formulation for lipid A analog E5531
    Asai, Y
    Watanabe, S
    DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY, 1999, 25 (09) : 975 - 982
  • [7] The effect of divalent cations on the membrane properties and pharmacokinetics in rat of the lipid A analogue E5531
    Asai, Y
    Sano, Y
    Kikuchi, K
    Iwamoto, K
    Watanabe, S
    JOURNAL OF PHARMACY AND PHARMACOLOGY, 2000, 52 (01) : 39 - 45
  • [8] Characterization of the physicochemical properties of aggregates of the lipid A analog, E5531, prepared by a 'pH-jump method'
    Asai, Y
    Iwamoto, K
    Watanabe, S
    CHEMISTRY AND PHYSICS OF LIPIDS, 1999, 97 (02) : 93 - 104
  • [9] A lipid A analog, E5531, blocks the endotoxin response in human volunteers with experimental endotoxemia
    Bunnell, E
    Lynn, M
    Habet, K
    Neumann, A
    Perdomo, CA
    Friedhoff, LT
    Rogers, SL
    Parrillo, JE
    CRITICAL CARE MEDICINE, 2000, 28 (08) : 2713 - 2720
  • [10] Development of freeze-dried injectable formulation for the novel lipid A analog, E5531
    Asai, Yasuyuki
    E-JOURNAL OF SURFACE SCIENCE AND NANOTECHNOLOGY, 2005, 3 : 169 - 172
12345